Abstract
This review highlights some recent advances in the design and development of matrix metalloproteinase inhibitors, especially those targeting MMP-2, MMP-9, and MMP-13. Various zinc-binding groups and non-zinc-binding groups are discussed. Interactions between residues in the critical S1' specificity pocket and MMP inhibitors are given special attention. The influence of ionization states of hydroxamates and retrohydroxamates on the docking outcome and the presence of zinc ions in the active site are explored in light of enhancing enrichment factors for docking studies. Details are given to structural factors for the development of more selective and more potent MMP inhibitors.
Keywords: MMP-2, MMP-3, MMP-13, rheumatoid arthritis, osteoarthritis, cancer, docking, and zinc binding group.
Current Pharmaceutical Design
Title:Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors
Volume: 19 Issue: 26
Author(s): Haizhen A. Zhong, Jack Arbiser and J. Phillip Bowen
Affiliation:
Keywords: MMP-2, MMP-3, MMP-13, rheumatoid arthritis, osteoarthritis, cancer, docking, and zinc binding group.
Abstract: This review highlights some recent advances in the design and development of matrix metalloproteinase inhibitors, especially those targeting MMP-2, MMP-9, and MMP-13. Various zinc-binding groups and non-zinc-binding groups are discussed. Interactions between residues in the critical S1' specificity pocket and MMP inhibitors are given special attention. The influence of ionization states of hydroxamates and retrohydroxamates on the docking outcome and the presence of zinc ions in the active site are explored in light of enhancing enrichment factors for docking studies. Details are given to structural factors for the development of more selective and more potent MMP inhibitors.
Export Options
About this article
Cite this article as:
Zhong A. Haizhen, Arbiser Jack and Bowen Phillip J., Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors, Current Pharmaceutical Design 2013; 19 (26) . https://dx.doi.org/10.2174/1381612811319260004
DOI https://dx.doi.org/10.2174/1381612811319260004 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design Elicitation of Immune Responsiveness Against Antigenic Challenge in Age- Related Diseases: Effects of Red Wine Polyphenols
Current Pharmaceutical Design Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Graphical Abstracts:
Anti-Cancer Agents in Medicinal Chemistry Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119
Current Radiopharmaceuticals Proteomic Level Changes on Treatment in MCF-7/DDP Breast Cancer Drug- Resistant Cells
Anti-Cancer Agents in Medicinal Chemistry Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis Synthesis of 1<i>H</i>-1,2,3-Triazole-Linked Quinoline-Isatin Molecular Hybrids as Anti-Breast Cancer and Anti-Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Agents
Anti-Cancer Agents in Medicinal Chemistry Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis
Current Pharmaceutical Design Combination Treatment of Glioblastoma by Low-Dose Radiation and Genistein
Current Radiopharmaceuticals Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma
Current Drug Discovery Technologies Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators
Current Cancer Drug Targets Poly (D,L-lactic-co-glycolide) Nanoparticles for the Improved Therapeutic Efficacy of All-trans-retinoic Acid: A Study of Acute Myeloid Leukemia (AML) Cell Differentiation In Vitro
Medicinal Chemistry Engineered Silver Nanoparticles, A New Nanoweapon Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Translation of CYP2D6 Human Genetic Variation into Medical Practice: Lessons Learned and the Way Forward
Current Pharmacogenomics and Personalized Medicine